Incidence and risk factors for hyperkalaemia in patients treated for COVID‐19 with nafamostat mesylate
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Clinical Pharmacy and Therapeutics"
DOI: 10.1111/jcpt.13646
Abstract: Nafamostat mesylate (NM) is used clinically in combination with antiviral drugs to treat coronavirus disease (COVID‐19). One of the adverse events of NM is hyperkalaemia due to inhibition of the amiloride‐sensitive sodium channels (ENaC). The… read more here.
Keywords: nafamostat mesylate; incidence risk; risk factors; factors hyperkalaemia ... See more keywords